C-reactive protein, ESR, and klebsiella in ankylosing spondylitis

P. COWLING, R. EBRINGER,¹ D. CAWDELL,¹ M. ISHII, AND A. EBRINGER

From the Immunology Unit, Department of Biochemistry, Queen Elizabeth College, London, and the ¹Departments of Microbiology and Rheumatology, Middlesex Hospital, London

SUMMARY Serum C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were measured on 469 occasions in 149 patients with ankylosing spondylitis who had also been investigated for faecal carriage of klebsiella/enterobacter species on the same occasions. Raised values of CRP and ESR correlated with each other (P<0·001) as well as with clinically assessed active disease episodes (P<0·001). Patients with positive cultures for klebsiella were found to have higher mean values for CRP and ESR than those with negative cultures (P<0·025). CRP appears to be a useful marker of disease activity in ankylosing spondylitis.

An association between clinically active inflammatory disease in ankylosing spondylitis (AS) and the presence in faeces of a Gram-negative micro-organism, Klebsiella pneumoniae, has been reported (Ebringer et al., 1977; Ebringer et al., 1978). Disease activity in those studies was assessed for each individual visit on the basis of the patient's assessment and the doctor's findings, laboratory and faecal culture results only being available later. Both ESR and CRP have been shown to be useful indicators of disease activity in other rheumatic diseases such as rheumatoid arthritis (Amos et al., 1977).

The function of CRP is unknown. It is produced in the liver and found only in low levels in normal human serum. High levels are found during acute infection, tissue injury, or inflammatory disease. The molecule is capable of activating the complement cascade and initiate both the opsonic and lytic potentials of this system (Siegel et al., 1975; Osmand et al., 1975; Mortensen et al., 1976). These characteristics suggest that CRP may play an important role in the mediation of inflammatory responses.

The value of CRP in ankylosing spondylitis has not been previously examined except in 1 early study (Glyn and Irving, 1959). In this investigation we set out to determine if ESR and CRP correlated or contributed to our understanding of disease in ankylosing spondylitis when compared both to the clinically assessed disease activity and the results of faecal culture.

Patients and methods

PATIENT SELECTION Serum samples were obtained from 149 patients attending the Middlesex Hospital AS clinics on 469 occasions. Each patient had an average of 3 visits (range 1–10). The patient's samples were selected randomly from a bank of serum samples obtained at regular visits over the past 2 years. The diagnosis of AS was made by the New York criteria (Bennet and Wood, 1968). Five patients with psoriatic spondylitis and 6 who had inflammatory bowel disease with spondylitis were included. Of 125 patients tissue typed 117 carried the B27 antigen. Two patients with colitic spondylitis and 2 with psoriatic spondylitis did not carry the B27 antigen. Six patients were included who had normal or suspicious sacroiliac x-ray changes with low back pain. All were HLA B27 positive and most had a positive family history, a positive sacroiliac scintiscan, or peripheral joint involvement. The mean age of all patients was 34·5 years (range 13–72), with a mode of 26 years. There were 33 female patients.

ASSESSMENT OF DISEASE ACTIVITY Assessment was done at the time of the patient's
visit and before the results of CRP, ESR, and faecal culture were available.

Assessment of active disease was made on the basis of acute peripheral manifestations such as active synovitis, dactylitis, joint or spinal tenderness, or acute anterior uveitis. If a patient had an effusion which was not tender or inflamed and which had been present for months, this was more likely to be assessed as probably active disease. Assessment of active disease was also made on the basis of recent (within the past 4 weeks) exacerbation of peripheral or spinal symptoms. Anti-inflammatory drug intake had usually increased, or the maintained dose had failed to control symptoms. There was nearly always worsening of the patient's self-rated visual analogue scale of pain.

Patients with probably active disease usually had symptoms which were stable or constant and were well controlled with anti-inflammatory therapy. Alternatively, they may have had more severe symptoms and signs in the previous few months and now appeared to be improving. Short fluctuations in symptoms in general were disregarded.

Patients assessed as having inactive disease were either symptomless or had only occasional mild or short-lived symptoms. They usually did not require medication or, if they did, the dose was regular and effective.

CONTROL SUBJECTS
Sixty healthy control subjects having no previous history of arthritis or back pain and not in a hospital environment were bled for estimation of serum CRP.

CRP ESTIMATIONS
The Mancini radial immunodiffusion technique with commercial antisera (Hoechst) was used. Each estimation was the mean of at least 2 separate measurements. All measurements were carried out without knowledge of the patient's clinical status.

ESR ESTIMATIONS
Blood for ESR was taken on the day of assessment and measured by the Westergren method. The normal hospital service was used and there was no special identification for the ESR samples measured.

FAECAL CULTURES
Faecal specimens were collected and cultured as described previously (Ebringer et al., 1978). Faecal cultures were read without knowledge of the patient's clinical status.

PATIENTS ON ANTIBIOTICS
Serum samples used also included patients who are on a trial of an antibiotic, Co-trimoxazole, at the time of assessment. These results were analysed separately when disease activity was assessed.

RESULTS
CRP AND DISEASE ACTIVITY
The mean serum CRP level in active patients was 32.78 ± 5.33 μg/ml (mean ± standard error of the mean), in probably active patients it was 27.64 ± 1.99 μg/ml, and in inactive patients it was 13.22 ± 0.82 μg/ml (Fig. 1). The difference in mean levels between active and inactive patients (t = 6.62, P<0.001), as well as between probably active and inactive patients (t = 7.33, P<0.001) was statistically significant.

The mean serum CRP level in 60 healthy control subjects was 3.57 ± 0.61 μg/ml. Of the 60 control subjects 31 (52%) had zero values for their serum CRP levels.

The difference in mean serum CRP levels between the 3 different disease activity groups in ankylosing spondylitis compared to healthy control subjects was statistically significant: active (t = 7.17, P<0.001) probably active (t = 6.82, P<0.001) and inactive (t = 5.68, P<0.001).
ESR and disease activity
The mean ESR in active patients was $37.10 \pm 5.99$ mm/h Westergren (mean ± standard error of the mean), in probably active patients $25.99 \pm 1.65$ mm/h, and in inactive patients $14.28 \pm 0.90$ mm/h (Fig. 2). The differences in mean ESR value between active and inactive patients ($t = 6.96$, $P < 0.001$) and probably active and inactive patients ($t = 6.62$, $P < 0.001$) were statistically significant.

Not only was there a correlation between mean CRP and mean ESR levels in various phases of disease activity, but individual values of high or low ESR were closely correlated with high or low values in serum CRP irrespective of disease activity ($r = +0.6947$, $DF = 430$, $P < 0.001$).

Isolation of klebsiella and disease activity
The results of culture investigations in patients with active, probably active, and inactive ankylosing spondylitis are summarised in Table 1. Klebsiella species of micro-organisms were isolated more frequently from patients during active or probably active phases than during inactive phases of ankylosing spondylitis. The difference between the isolation rate of klebsiella in active patients compared to inactive patients was statistically significant (Yates's correction, chi-square $= 5.02$, $P < 0.025$), but not significant when probably active patients were compared to inactive patients (Yates's correction, chi-square $= 3.01$, NS).

This study, however, included some patients who were taking antibiotics. If the episodes where patients were taking antibiotics are excluded (Table 1), the frequency of isolation of klebsiella micro-organisms increases in all 3 categories of disease activity. The difference between the isolation of klebsiella in both active (Yates's correction, chi-square $= 9.18$, $P < 0.005$) and probably active (Yates's correction, chi-square $= 5.07$, $P < 0.025$) patients not taking antibiotics is statistically significant when compared to a similar group of inactive patients.

CRP and ESR in patients with and without klebsiella
All the episodes in patients in whom klebsiella was isolated from faecal cultures were grouped together irrespective of disease activity and compared to all the episodes when no klebsiella was isolated. The mean serum CRP in patients having klebsiella was $25.17 \pm 2.91 \mu g/ml$ (mean ± standard error of the mean), while in patients not having klebsiella it was $18.57 \pm 1.21 \mu g/ml$ (Fig. 3), and this difference is statistically significant ($t = 2.48$, $P < 0.01$). The mean ESR in patients having klebsiella in their faeces was $24.15 \pm 2.56$ mm/h, while in patients not having klebsiella it was $18.78 \pm 1.13$ mm/h (Fig. 4), and this difference is statistically significant ($t = 2.21$, $P < 0.025$).

Discussion
Our findings show that patients with AS have raised
CRP and ESR values comparable to the values found in patients with rheumatoid arthritis (Amos et al., 1978). Those patients with clinically assessed active disease have higher mean CRP and ESR results than patients with clinically less active disease. Moreover the presence of klebsiella/enterobacter in the faeces is associated with a higher mean CRP and ESR irrespective of the clinically assessed disease activity. Thus there is an association between the presence of klebsiella in AS patients and active disease as assessed independently by clinical and laboratory criteria.

Our clinical assessment of disease activity was deliberately aimed at selecting episodes of acute inflammatory disease whether these were episodes of acute anterior uveitis, peripheral arthritis, spinal disease, or a combination of the three. It is more difficult to assess such active episodes when the symptoms relate to pelvic or spinal disease alone, and it is for this reason that recent worsening of symptoms played a major role in guiding the grading of disease activity.

Clinical observation suggests that AS is not an inexorable progressive disease and that it follows a pattern of exacerbations and remissions. The sacroiliitis and spinal disease as evidenced by limitation of movement and radiographic changes would, under this hypothesis, more probably reflect the gradual accumulation of partially irreversible, chronic secondary changes due to the initial inflammatory episodes. It is possible that each major flare-up of disease in the patient, whether acute anterior uveitis, peripheral arthritis, or spinal inflammation, may be due to reinfection or rechallenge by the agent or agents responsible for triggering the inflammation. This hypothesis therefore suggests that ankylosing spondylitis and the episodes of acute anterior uveitis associated with AS and HLA B27 are due to a form of reactive arthritis or reactive inflammation, probably immunologically mediated. Klebsiella pneumoniae may be one of the micro-organisms which trigger off such exacerbations of inflammatory joint or eye disease.

The best model of reactive arthritis is acute rheumatic fever. In this disease there is a clear difference between the acute rheumatic symptoms occurring several weeks after a streptococcal throat
infection and the disability due to incompetent or stenosed cardiac valves of chronic rheumatic heart disease. We would suggest that there is an analogy here between the acute inflammatory episode and the chronic diseased valves and the acute inflammatory episodes of AS and the sacroiliitis and spondylitis of established disease. The search for an aetiological agent in rheumatic fever would have been unrewarding if only patients with established rheumatic heart disease were studied. Similarly we anticipated that the 'active disease' or acute inflammatory episodes in AS were the times to search for potential aetiological agents.

The pathogenesis of AS is still unclear. If we assume that an infective micro-organism is involved, the pathological lesion of AS could be produced either directly by infection or by release of toxins or bacterial debris from the implicated gut microorganisms such as klebsiella/enterobacter species, salmonella, shigella, or Yersinia enterocolitica. Another possible mechanism is that partially cross-reacting antibodies binding to self antigens are produced, triggering the complement cascade and producing localised inflammation at a site distal to the site of infection. All 3 mechanisms may play a role. We favour the cross-reactivity mechanism (Ebringer, 1978; Young et al., 1978).

In rheumatic fever, the infection is located in the upper respiratory tract, and inflammatory damage mediated by cross-reacting antistreptococcal antibodies occurs in brain and endomyocardium, producing chorea and rheumatic heart disease. In ankylosing spondylitis the infection might be located in the lower gastrointestinal tract, and inflammatory damage, triggered by cross-reacting antimicrobial antibodies, might occur in joint, spine, and eyeball, producing sacroiliitis and uveitis. Whether such antibody can be demonstrated remains to be seen.

We thank Dr G. Panayi for his helpful discussions during this study and Mrs Coralie Padamsey for typing the manuscript.

References


C-reactive protein, ESR, and klebsiella in ankylosing spondylitis.
P Cowling, R Ebringer, D Cawdell, M Ishii and A Ebringer

Ann Rheum Dis 1980 39: 45-49
doi: 10.1136/ard.39.1.45

Updated information and services can be found at:
http://ard.bmj.com/content/39/1/45

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/